Sopharma has agreed to acquire Pharmanova, a Serbian-based pharmaceutical company

Sopharma has signed a contract for the phased acquisition of the Serbian-based pharmaceutical manufacturer Pharmanova. The deal is structured in three steps, starting with the acquisition of 25% interest in December 2023, which is increased to 75% in 2024 and to 100% in 2025. With this transaction, Sopharma will further strengthen its market position in the Balkans and add to its family of businesses one of the biggest producers of branded herbal medicines and dietary products in Serbia.

Sopharma is a leading producer and distributor of healthcare products in the CEE region, with a vertically integrated business model running through the whole value chain, having its own R&D, manufacturing, and wholesale and retail distribution. The company is present in 33 countries and has a product portfolio of more than 200 products.

Founded in 1991, Pharmanova manufactures generic and over-the-counter drugs, dietary supplements, ointments and medical devices. It serves the markets of Serbia, Bosnia and Herzegovina, Montenegro and North Macedonia.

Oaklins’ team in Bulgaria acted as the buy-side advisor to Sopharma, leading the transaction process, deal structuring and negotiations, and assisting throughout the course of the acquisition.